2019 Anti-obesity Drugs Market Future Growth Rate by Market Current Strategy, Top Most Players, and Regional Segmentation by Forecast to 2024

Anti-obesity Drugs

The primary goal of this Global Anti-obesity Drugs Market report is to maintain the record of Unusual growth strategies adopted by various companies are creating new standards for competition in the global Anti-obesity Drugs market. Businesses around the world are aiming at increasing their profit margin and establishing a stronghold in the global market. The impact of prevailing regulatory scenario on both regional and worldwide Anti-obesity Drugs market is provided in detail in the report.

Get Sample Copy of Anti-obesity Drugs Market Report @ https://www.industryresearch.co/enquiry/request-sample/13999607

Key Market Trends:

OTC Drugs Segment is Expected to Exhibit Fastest Growth Rate over the Forecast Period

In the present scenario, the weight problem is a major concern, globally. The rising intake of junk food/fast food is resulting in declining healthiness worldwide. As mentioned earlier, obesity is one of the most prevalent problems faced by people of this century. According to WHO, in 2016, more than 1.9 billion adults, ranging between 18 years and older, were overweight. Out of the aforementioned numbers, over 650 million were obese. With intentions to offer weight loss solutions, the companies have developed a number of weight loss products, of which a considerable proportion are OTC drugs.

In most countries, Orlistat is marketed as a prescription drug under the trade name Xenical, by Roche, and it is sold as an OTC drug under the trade name Alli, by GlaxoSmithKline, in the United Kingdom and the United States. Currently, the number of OTC drugs approved in the market is very less. However, the cost-effectiveness and ease of availability of OTC products are expected to propel the growth of the market.

North America Captured the Largest Market Share and is Expected to Retain its Dominance

North America dominated the global anti-obesity drugs market, with the United States accounting for the major contributor to the market. The primary factors driving the growth of the market studied are an increase in obese population and high healthcare spending. In the past few decades, several anti-obesity drugs are withdrawn from the market, due to reported and documented adverse effects. After years of interruption, the US Food and Drug Administration (FDA) has recently approved multiple new anti-obesity drugs. Majority of these medications are administered orally, and only one is administered subcutaneously. According to the data published by the Centers for Disease Control and Prevention (CDC), the prevalence of obesity was 39.8% and affected about 93.3 million US adults in 2015-2016, hence propelling the anti-obesity drugs market.

Anti-obesity Drugs Market Covers Key Players:

  • Arena Pharmaceuticals
  • GlaxoSmithKline
  • Nalpropion Pharmaceuticals Inc.
  • F Hoffmann
  • La Roche
  • Vivus
  • Bayer AG
  • Novo Nordisk
  • Pfizer
  • Eisai

    Ask for Discount at https://www.industryresearch.co/enquiry/request-discount/13999607

    Geographical Landscape:

    This Report Focuses on the Anti-obesity Drugs in the Global market, especially in North America, China, Europe, Japan, Southeast Asia, India. This report categorizes the market based on manufacturers, regions, type, and application

    Market Overview:

  • The anti-obesity drugs market is growing steadily with the gradual growth in the number of approvals from the US FDA and Europe EMA. North America, especially the United States, dominates this market, due to better healthcare services and high expenditure, followed by Europe. Till 2012, Xenical (orlistat) and generic phentermine were among the only approved drugs. However, the period between 2012 and 2016 saw high growth in the number of major pharmaceutical companies investing largely on clinical trials. However, there are still very fewer drugs in the late stage of development.
  • Owing to the less success rate and withdrawal among the centrally acting drugs, several of the major companies have considered the development of anti-obesity drugs as prohibitively risky and shifted the companies’ inclination toward broadening the scope of a diabetic portfolio into obesity. Since several companies have developed a strong relationship between Type 2 diabetes and obesity, it is often considered to be a low-risk strategy and minor investments in the R&D for potential anti-obesity drugs. Currently, the market is gradually growing its authority in the developing regions with the gradual approval of drugs, globally. However, it holds great potential with the aforementioned advantages, as several companies are targeting dual therapy mode for the treatment of obesity.
  • Report Highlights:

    – The report provides a detailed analysis on current and future market trends to identify the investment opportunities

    – Market forecasts till 2024, using estimated market values as the base numbers

    – Key market trends across the business segments, Regions and Countries

    – Key developments and strategies observed in the market

    – Market Dynamics such as Drivers, Restraints, Opportunities and other trends

    – In-depth company profiles of key players and upcoming prominent players

    – Growth prospects among the emerging nations through 2024

    – Anti-obesity Drugs Market opportunities and recommendations for new investments

    Price Of Report: $ 4250 (SUL)

    Purchase Anti-obesity Drugs Market Report @ https://www.industryresearch.co/purchase/13999607

    Detailed TOC of Anti-obesity Drugs Market Research Report 2019 – 2024:

    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study



    4.1 Market Overview
    4.2 Market Drivers
    4.2.1 Increase in Prevalence of Obesity
    4.2.2 Sedentary Lifestyle
    4.3 Market Restraints
    4.3.1 Availability of Alternative Treatment Options
    4.3.2 Side Effects of Drugs
    4.3.3 High Drug Development Costs
    4.4 Industry Attractiveness- Porter’s Five Forces Analysis
    4.4.1 Threat of New Entrants
    4.4.2 Bargaining Power of Buyers/Consumers
    4.4.3 Bargaining Power of Suppliers
    4.4.4 Threat of Substitute Products
    4.4.5 Intensity of Competitive Rivalry

    5.1 Mechanism of Action
    5.1.1 Peripherally Acting Anti-obesity Drugs
    5.1.2 Centrally Acting Anti-obesity Drugs
    5.2 Drug Type
    5.2.1 Prescription Drugs
    5.2.2 OTC drugs
    5.3 Geography
    5.3.1 North America United States Canada Mexico
    5.3.2 Europe United Kingdom Germany France Italy Spain Rest of Europe
    5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
    5.3.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
    5.3.5 South America Brazil Argentina Rest of South America

    6.1 Company Profiles
    6.1.1 Arena Pharmaceuticals
    6.1.2 GlaxoSmithKline
    6.1.3 Nalpropion Pharmaceuticals Inc.
    6.1.4 F Hoffmann-La Roche
    6.1.5 Vivus
    6.1.6 Bayer AG
    6.1.7 Novo Nordisk
    6.1.8 Pfizer
    6.1.9 Eisai


    About Industry Research:

    Industry Research is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in-depth market research. We are one of the top report resellers in the market, dedicated to bringing you an ingenious concoction of data parameters.

    Contact Us:

    Name: Ajay More

    Organization: Industry Research

    Phone: +44 20 3239 8187 / +14242530807

    Email: [email protected]

    Our latest Report: Drinking Water Market 2019 Offers Newest Industry Data, Industry Future Trends, Sales, Revenue, Growth Rate by Types and Applications Forecast till 2023